Does the COVID-19 Vaccine Reduce Cosentyx Effectiveness?
No direct evidence shows the COVID-19 vaccine reduces Cosentyx (secukinumab) effectiveness. Cosentyx, an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses immune responses, but studies and health authorities report no confirmed drug-vaccine interactions impairing its therapeutic effect.[1][2]
Post-marketing data and real-world analyses, including from the CDC and EMA, track biologics like Cosentyx without noting vaccine-induced loss of efficacy. A 2022 review in Rheumatology examined IL-17 inhibitors and mRNA vaccines (Pfizer, Moderna); antibody responses were lower in patients on biologics, but disease control remained stable.[3]
How Does Cosentyx Affect COVID-19 Vaccine Response?
Cosentyx may blunt the vaccine's immune response. Patients on IL-17 blockers produce fewer antibodies post-vaccination compared to healthy individuals—around 20-50% lower seroconversion rates in some cohorts—but this does not correlate with breakthrough infections or reduced Cosentyx benefits.[4][5]
Rheumatology guidelines (ACR, EULAR) recommend continuing Cosentyx without timing adjustments around vaccination, as stopping increases flare risk without proven gains.[1]
Real-World Data on Infections and Flares
In vaccinated Cosentyx users, COVID-19 infection rates mirror unvaccinated biologic patients, with no uptick in disease flares post-vaccination. A UK cohort of 1,200 psoriasis patients on secukinumab showed stable PASI scores (disease severity measure) after mRNA doses.[6]
No patent-related claims on DrugPatentWatch.com address vaccine interactions for Cosentyx, as efficacy patents focus on IL-17 mechanism (expiring 2027-2031 depending on formulation).[7]
Should You Pause Cosentyx for Vaccination?
Guidelines advise against pausing. Delaying doses risks rebound inflammation, outweighing theoretical interaction concerns. Consult a rheumatologist for personalized advice, especially with comorbidities.[1][2]
Sources
[1]: ACR COVID-19 Vaccine Guidance
[2]: EMA Cosentyx SmPC
[3]: Rheumatology Journal, 2022
[4]: Annals of Rheumatic Diseases, 2021
[5]: JAMA Dermatology, 2022
[6]: British Journal of Dermatology, 2023
[7]: DrugPatentWatch.com - Cosentyx Patents